Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit
NEWARK, Calif., Oct. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer and Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology will participate in a fireside chat at the upcoming Jefferies Next Generation IBD Therapeutics Summit taking place virtually on October 19, 2021.
Presentation details:
Date: Tuesday, October 19, 2021
Time: Available on-demand starting at 10:45 a.m. EST
A webcast of the event will be available for 90 days on the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.
About Protagonist Therapeutics
Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform.
Protagonist's pipeline includes rusfertide (PTG-300), an investigational, injectable hepcidin mimetic currently in a Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), a Phase 2 study in PV subjects with high hematocrit levels, and a Phase 2 study for hereditary hemochromatosis. The Company plans to initiate a single, global Phase 3 randomized, placebo-controlled trial evaluating the efficacy and safety of a once weekly, subcutaneously self-administered dose of rusfertide.
The Company is also evaluating an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide (PN-943) currently in a Phase 2 study in adults with moderate to severe active ulcerative colitis (UC). The Company is targeting ulcerative colitis as the initial indication.
The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of oral peptide IL-23 receptor antagonists. Compounds included in this agreement are PTG-200, PN-235 and PN-232. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. PN-235 and PN-232, both second-generation oral interleukin-23 receptor antagonist candidates, are currently in Phase 1 studies.
Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-jefferies-next-generation-ibd-therapeutics-summit-301397480.html
SOURCE Protagonist Therapeutics, Inc.
